Galmed Pharmaceuticals, a clinical-stage biotech developing therapies for liver diseases and gallstones, filed on Thursday with the SEC to raise up to $35 million in an initial public offering. The Tel Aviv, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol GLMD. Galmed Pharmaceuticals initially filed confidentially on December 31, 2013. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.
